Evidence map›Paper›PMID 33255376›Full record

ReviewInternational journal of molecular sciences2020

Lipid Rafts and Dopamine Receptor Signaling.

Victor J Martinez, Laureano D Asico, Pedro A Jose, Andrew C Tiu

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 23 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. G Protein-Coupled Receptor Dimerization-What Next?International journal of molecular sciences · 2024
    Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Dopamine, Immunity, and Disease.Pharmacological reviews · 2023
    Review
  10. Article
  11. The Role of Lipids in Allosteric Modulation of Dopamine DMolecules (Basel, Switzerland) · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Victor J MartinezDepartment of Medicine, Einstein Medical Center Philadelphia, Philadelphia, PA 19141, USA.ORCID 0000-0002-7343-0808
Laureano D AsicoDivision of Renal Diseases & Hypertension, Department of Medicine, The George Washington University School of Medicine & Health Sciences, Washington, DC 20052, USA.
Pedro A JoseDivision of Renal Diseases & Hypertension, Department of Medicine, The George Washington University School of Medicine & Health Sciences, Washington, DC 20052, USA.
Andrew C TiuDepartment of Medicine, Einstein Medical Center Philadelphia, Philadelphia, PA 19141, USA.
Einstein Medical Center Philadelphia · USGeorge Washington University · US

Funding

Spatiotemporal transregulation of D1-like angiotensin receptors in genetically...P01HL074940 · NHLBI · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI GILDEA, JOHN JOSEPH · 2004 to 2020
$31.8M
RENAL DOPAMINE-1 RECEPTOR DEFECT IN HYPERTENSIONR01DK039308 · NIDDK · UNIVERSITY OF MARYLAND BALTIMORE · PI JOSE, PEDRO A. · 1987 to 2020
$7.4M
Lipid rafts, dopamine 1 receptor, and hypertensionR01DK119652 · NIDDK · GEORGE WASHINGTON UNIVERSITY · PI JOSE, PEDRO A. · 2020 to 2023
$2.6M
NHLBI NIH HHS P01 HL074940NIDDK NIH HHS R01 DK039308NIDDK NIH HHS R01 DK119652
6 · The paper itself

Abstract

The renal dopaminergic system has been identified as a modulator of sodium balance and blood pressure. According to the Centers for Disease Control and Prevention, in 2018 in the United States, almost half a million deaths included hypertension as a primary or contributing cause. Renal dopamine receptors, members of the G protein-coupled receptor family, are divided in two groups: D1-like receptors that act to keep the blood pressure in the normal range, and D2-like receptors with a variable effect on blood pressure, depending on volume status. The renal dopamine receptor function is regulated, in part, by its expression in microdomains in the plasma membrane. Lipid rafts form platforms within the plasma membrane for the organization and dynamic contact of molecules involved in numerous cellular processes such as ligand binding, membrane sorting, effector specificity, and signal transduction. Understanding all the components of lipid rafts, their interaction with renal dopamine receptors, and their signaling process offers an opportunity to unravel potential treatment targets that could halt the progression of hypertension, chronic kidney disease (CKD), and their complications.

Indexed as

Blood PressureCell MembraneDopamineHumansHypertensionKidneyMembrane MicrodomainsReceptors, Dopamine D1Receptors, Dopamine D2Signal TransductionSodiumDopamineReceptors, Dopamine D1Receptors, Dopamine D2Sodiumdopamine receptorG proteinlipid raftssignaling

Identifiers

PMID33255376
PMCPMC7727868
OpenAlexW3110213808

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.